Serum alpha-L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma

Giardina, M. G.; Matarazzo, Margherita; Varriale, Antonio; Morante, R; Napoli, Antonia Passarelli di; Martino, R.

doi:10.1002/1097-0142(19920901)70:5<1044::aid-cncr2820700506>3.0.co;2-u

Cited by 58 publications

(47 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are some reports that have indicated that AFP has low sensitivity and specificity for its high false-positive and false-negative rates and is, therefore, only of limited utility in differentiating HCC from benign hepatic disorders (Zhou et al, 2006); these authors noted that patients with acute exacerbation of viral hepatitis but no HCC may also have markedly increased AFP levels. To improve sensitivity and specificity of any clinical detection, other biomarkers have been utilized (in addition to AFP) including measures of a-fucosidase lysosomal enzyme (Giardina et al, 1992) and of hepatocyte-produced pro-inflammatory cytokines (such as IL-2, -6, and -8) (Falasca et al, 2006). In the current study, AFP-as a differentiating marker between cirrhotic and HCC-bearing patients-had a 100% sensitivity and 86% specificity.…”

Section: Discussionsupporting

confidence: 63%

Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Hammad¹,

Abdelraouf²,

Hassanein

et al. 2013

Journal of Immunotoxicology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infects primarily hepatocytes, leads to development of fibrosis and/or cirrhosis of the liver and is a significant factor for developing hepatocellular carcinoma (HCC). Evidence indicates that liver fibrosis contains uncontrolled inflammation as a part of its etiology. Normal cell-mediated immunity plays a central role in the mechanisms involved in viral clearance/persistence in the liver. In this context, cytokines modulate the immune system and exert direct anti-viral activity. To this end, this study investigated potential associations of serum IL-17 and IL-6 with exacerbation of hepatic damage in chronic HCV patients to determine their utility as prognostic markers for potential development of HCC. Chronic HCV-patients were recruited, divided into groups according to degree of liver damage, i.e. patients with perihepatic fibrosis, hepatic cirrhosis, or HCC, and had their blood collected for analysis of liver function and serum IL-6 and IL-17 levels. Interestingly, increases in serum IL-17 levels in the study groups were associated with aggravation of the clinical state from HCV to cirrhosis and then to HCC. Serum IL-6 levels followed a similar pattern. The association of both cytokines with progressive exacerbation of the initial HCV-induced liver damage was further confirmed by correlation analysis that revealed positive correlations between HCV RNA titer and IL-17 (þ0.951, p50.05) and IL-6 (þ0.85, p50.05). A receiver operating characteristics (ROC) analysis revealed their beneficial addition as promising biomarkers for a better prognostic profile of HCC. Interestingly, a significant progressive decline in the active vitamin D status was noted in all three clinical states, and these too were associated with progressive liver disease. This study confirms the necessity of adding screening for IL-6 and IL-17 and vitamin D to that of the classic marker AFP for patients with HCV and cirrhosis to hopefully permit clinicians to initiate measures that ultimately might mitigate/delay development of HCC in these infected patients.

show abstract

Section: Discussionsupporting

confidence: 63%

Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Hammad¹,

Abdelraouf²,

Hassanein

et al. 2013

Journal of Immunotoxicology

View full text Add to dashboard Cite

show abstract

“…Nevertheless, this explanation is not supported by recent studies that show a decrease of AFU expression in tumoral liver tissues compared to normal tissues [54]. AFU measurement is useful in association with AFP in the early diagnosis of HCC [55]. Moreover, there is a positive correlation between AFU levels and tumor size in HCC patients [56].…”

Section: Human Carbonyl Reductasementioning

confidence: 99%

Serum Markers of Hepatocellular Carcinoma

et al. 2010

View full text Add to dashboard Cite

Despite the large number of studies devoted to the immunohistochemistry of HCC, at the present time, the absolute positive and negative markers for HCC are still lacking, and even those characterized by very high sensitivity and specificity do not have an universal diagnostic usefulness. Given the poor response to current therapies, a better understanding of the molecular pathways active in this disease could potentially provide new targets for therapy. However, AFP shows a low sensitivity, therefore other biomarkers have been developed to make an early diagnosis and improve patients' prognosis.

show abstract

“…All samples were studied following the completion of the collection period; however, AFU activity was assayed within 30 days after collection (17). This step was taken to avoid any possible alterations in AFU activity after this period (18).…”

Section: Ii-human Studymentioning

confidence: 99%

Priority of Alpha-L- Fucosidase Over Alpha fetoprotein in Early Detection of Hepatocellular Carcinoma in Animals and Human

Hamid¹,

Nazmy²,

Moustafa³

et al. 2014

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETAmaç: Erken tanı hepatoselüler karsinom (HCC) tedavisindeki en kritik adımdır. Çalışmada erken tanıda alfa-L-fukosidazın (AFU) klasik belirteç olan alfa-fetoproteine (AFP) kıyasla güvenilirliği incelenmiştir. Gereç ve Yöntem: Teorimizi kanıtlamak için çalışma hem insan hem de hayvan örneklemler kullanılacak şekilde planlanmıştır. Çalışmanın hayvan deneyi ayağında 60 Wistar faresi kontrol grubu ve 8, 16, 24 hafta dietilnitrozamine (DENA) verilen gruplar olmak üzere 4 gruba ayrılmıştır. İnsan çalışma grubu kontrol ve hafif, ileri ve metastatik olarak 4 gruba bölünen toplam 120 hastadan oluşmaktadır. Histolojik ve biyokimyasal analizler (AFP, AFU, karaciğer fonksiyon testleri, total antioksidan serum seviyeleri) ve ROC eğrileri ile korelasyon analizleri insan ve hayvan gruplarında yapılmıştır. Bulgular: DENA-tedavi grubu zamana bağlı olarak belirgin histopatolojik değişiklikler göstermiştir. Kontrol grubu ile kıyaslandığında 6 hafta sonra bilirubin ve total antioksidanlar dışındaki tüm biyokimyasal parametrelerde, 8 hafta sonra bilirubin, albumin, AFP ve total antioksidanlar dışındaki parametrelerde ve 24 hafta sonra ise tüm biyokimyasal parametrelerde (AFP, AFU, karaciğer fonksiyon testleri ve total antioksidan serum düzeylerinde) anlamlı değişiklikler saptanmıştır. Histolojik olarak sınıflandırılmış tüm HCC gruplarının tün incelenen parametrelerinde istatistiksel olarak anlamlı sonuçlar saptanmıştır. Sınır olarak 5 μmol/l/min kabul edildiğinde ROC analizi ile yapılan incelemede AFU %90 sensitivite, %92 spesifite göstermiştir ve %91 tanısal doğruluk göstermiştir. Sınır değer 60 ng/ml olarak alındığında ise sensisivite, spesifite ve tanısal doğruluk sıraıyla %60, %76 ve %68 olarak saptanmıştır. AFU ile ALT, AST ve AFP ilişki katsayıları istatistiksel olarak anlamlıdır. Sonuç: HCC erken tanısında erken tanıda AFU, AFP'den daha iyi bir belirteçtir. AFU sensitivite, spesivitesi daha yüksek olup diğer indekslerle AFP'ye kıyasla daha iyi korele olmuştur. İnsandan elde edilen sonuçlar teorimizi doğrulamıştır. Anahtar Kelimeler: Hepatoselüler karsinom; Dietilnitrozamine; Alpha-L-fucosidase; Alpha-fetoprotein; Antioksidan seviyesi; Erken tanı ABSTRACT Objective: Early detection of hepatocellular carcinoma (HCC) is the most critical step in the management process. We try to provide new insights about the possible role of alpha-L-fucosidase (AFU) to achieve more reliable detection of HCC over a classical marker alpha fetoprotein (AFP). Methods: The study included both animal and human subjects, to legislate our theory. In animal study, 60 Male Wistar rats were classified to control, other 3 groups received di ethyl nitrosamine (DENA) for 8, 16, 24 weeks respectively. In human study: one hundred and twenty patients were assigned as: control group, 3 groups with histologically graded HCC, into mild, advanced and metastatic HCC. Histological and biochemical analysis (AFP, AFU, liver function tests, total antioxidant serum levels) in both animals and patients, as well as, receiver operating characteristic (ROC) curves and co...

show abstract

Serum alpha-L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma

Cited by 58 publications

References 14 publications

Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis?

Serum Markers of Hepatocellular Carcinoma

Priority of Alpha-L- Fucosidase Over Alpha fetoprotein in Early Detection of Hepatocellular Carcinoma in Animals and Human

Contact Info

Product

Resources

About